GENE ONLINE|News &
Opinion
Blog

Heart Disease
‘Heart Attack on a Chip’ Sheds Light on Personalized Drugs Trials
2022-12-14
Bristol Myers Squibb’ sNDA for Rare Heart Disease Treatment Accepted by the FDA
2022-10-21
Potential Novel Anti-thrombotic Treatment by Ionis Pharmaceuticals
2022-07-28
Cytokinetics Poised to Begin Phase 3 after its HCM Drug Registers Encouraging Data
2021-07-21
Verve Makes Successful Wall Street Debut on Back of its Promising Base Editor
2021-06-20
With $41.9 Million from Oversubscribed Financing Round, XyloCor Sets Sights on Gene Therapy for Heart Disease
2021-03-23
Tenaya Raises $106 Million Series C Round To Fight Heart Disease
2021-03-04
Verve Raises $94M in Series B, Aims to Disrupt Cardiology Market with ‘Once-and-Done’ Gene Editing Therapies
2021-01-21
Why is Bristol Myers Squibb Investing $13.1 Billion in MyoKardia?
2020-10-06
Encouraging Performance of Cardiovascular Drug Vindicates Novartis’ $9.7 Billion Buyout Deal
2020-09-06
Verve Therapeutic’s One Time Base Editing Treatment Cuts Down Cholesterol Levels in Blood
2020-06-30
Weekly in Asia |Nov
2019-11-12
LATEST
Should People Looking to Lose Weight Skip Sugar Substitutes?
2023-05-30
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
2023-05-26
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
2023-05-25
CDC Calls an End to J&J’s COVID-19 Vaccine in the U.S.
2023-05-25
A Close Look at the Evolution of ESG in Biopharma
2023-05-22
Scientists Identified Potential New Drugs to Combat Blindness
2023-05-21
FDA Approves Astellas’ Non-hormonal Menopause Treatment After Extended Review
2023-05-19
EVENT
2023-05-16
The 2nd International Healthcare Week
Hong Kong , China
2023-06-02
2023 ASCO annual meeting
Chicago, USA
2023-07-26
BIO Asia-Taiwan 2023
Taipei, Taiwan
2023-09-06
2023 Bio Asia Pacific
Bangkok, Thailand
Scroll to Top